Last Updated: 09 Nov 2024
Executive Summary
Immuron Ltd ADR (IMRN) is a biopharmaceutical company developing oral immunotherapy polyclonal antibodies for treating and preventing infectious and immunomodulated diseases. With a market capitalization of $11.72 million, the company reported a revenue of $4.90 million in the latest quarter ended September 30, 2024. Despite revenue growth, IMRN faces challenges with negative earnings and profitability margins. The stock's current price of $1.82 is below its 52-week high of $5.96.
Company Overview
Immuron Ltd is headquartered in Carlton, Australia, and focuses on researching and developing oral immunotherapy polyclonal antibodies. The company's products target infectious and immunomodulated diseases, including traveler's diarrhea, inflammatory bowel disease, and asthma. Immuron has a presence in Australia, the United States, and internationally.
Fundamental Analysis
Revenue: IMRN's revenue has grown 1.086% year-over-year to $4.90 million in the latest quarter.
Earnings: The company reported a loss per share of $0.80 in the latest quarter, with a negative EBITDA of $5.21 million.
Profitability: IMRN's profit margins remain negative, with a gross profit margin of -1.415% and an operating margin of -1.32%.
Valuation: The stock is trading at a price-to-sales ratio of 2.391, a price-to-book ratio of 1.243, and an EV-to-revenue ratio of 1.238.
Technical Analysis
Trend: IMRN's stock price has been trending lower in recent months.
Moving Averages: The stock is trading below its 50-day and 200-day moving averages.
Support and Resistance: The stock has support at $1.59 and resistance at $2.354.
Short Term Outlook
In the short term, IMRN's stock price could face further downward pressure due to its negative earnings and profitability. The stock's technical indicators also suggest a bearish trend.
Long Term Outlook
The company's long-term outlook depends on its ability to improve its financial performance and gain market share in its target markets. If IMRN can successfully commercialize its products and achieve profitability, it could see its stock price recover.
Analyst Recommendations
Currently, one analyst has a "Buy" rating on IMRN, with a target price of $5.08. The analyst cites the company's potential in the oral immunotherapy market as a reason for their positive outlook.
